A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(31 sites) China
Anhui Provincial Hospital, Anhui Beijing Tiantan Hospital, Capital Medical University, Beijing Beijing University Cancer Hospital, Beijing The Fifth Medical Center of Chinese PLA General Hospital, Beijing Jilin Cancer Hospital, Changchun Hunan Cancer Hospital, Changsha Hunan Second People's Hospital, Changsha Sichuan Cancer Hospital, Chengdu Chongqing University Cancer Hospital, Chongqing Fujian Cancer Hospital, Fuzhou Sun Yat-sen University Cancer Center, Guangzhou The Second Affiliated Hospital of Guilin Medical University, Guilin Zhejiang Cancer Hospital, Hangzhou Harbin Medical University Cancer Hospital, Harbin Jinan Central Hospital, Jinan Qilu Hospital of shangdong university, Jinan Shandong Cancer Hospital, Jinan Meizhou People's Hospital, Meizhou Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute, Nanning Nanyang City Center Hospital, Nanyang Nanyang Second General Hospital, Nanyang Shanghai Pulmonology Hospital, Shanghai Liaoning Cancer Hospital & Institute, Shenyang Shengjing Hospital of China Medical University, Shenyang Shanxi Provincial Tumor Hospital, Taiyuan Tongji Hospital, Tongji Medical College of HUST, China, Wuhan Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Yunnan Cancer Hospital, Yunnan Henan Cancer Hospital, Zhengzhou The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Last updated January 2025